Answers are grounded in this paper and cite their sources.
Pancreatic cancer is one of the most lethal malignancies, largely due to late-stage diagnosis and the absence of accessible screening tools. Conventional diagnostic approaches, including imaging and biopsy, are costly, invasive, and unsuitable for routine monitoring, while standard biochemical assays remain time-consuming and laboratory dependent. Therefore, rapid, sensitive, and non-invasive detection of pancreatic cancer biomarkers is critically needed. Here, we report a nanoengineered electrochemical aptasensor integrated with an automated urine analysis platform (“UroSmart”) for point-of-care (PoC) detection of carbohydrate antigen 19.9 (CA19.9). The UroSmart system incorporates a closed-loop, urine collection module and precisely controlled microfluidic dispensing system, facilitating seamless aseptic integration of sample collection, processing, and analysis within a single platform. The sensing interface uses an aptamer on gold nanoparticle-modified electrodes to improve target recognition and signal transduction. Upon sample introduction, CA19.9 is selectively captured at the electrode surface, leading to a measurable decrease in interfacial conductivity for quantitative electrochemical readout. Under optimised conditions, the platform exhibits high specificity, a wide dynamic range, and stable performance across varying physiological conditions. The limit of detection (LoD) was 0.47 U mL −1 in buffer and 2.02 U mL −1 in human urine, with a broad linear dynamic range spanning 0.1–1000 U mL −1 .The integrated system enables a novel rapid, sample-in-result-out analysis, demonstrating strong potential as a reliable PoC tool for early detection and longitudinal monitoring of pancreatic cancer at the asymptomatic stage.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: